Conference Track

Hepatitis and Opportunistic Diseases

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Interferon-γ Release Assay Effective for Detecting Latent TB Infection in HIV-Infected Individuals, Except Those With Low CD4+ Cell Counts
Mortality Associated With Advanced Immunodeficiency Suggests Need for Prompt Antiretroviral Therapy in HIV-Infected Patients Diagnosed With TB
Type of AIDS-Defining Event Diagnosed Strongly Associated With Risk of Mortality in the ART Cohort Collaboration
The Anti-HBV Drug Entecavir Inhibits HIV-1 Replication and Can Select for M184V
Lower Insulin Resistance at Baseline Predicts Rapid Virologic Response in HIV/HCV-Coinfected Patients Treated With Peginterferon and Ribavirin
ACTG 5170: Neurocognitive Function Maintained During HAART Interruption in Patients With CD4+ Cell Counts > 350 cells/mm³
Risk of HCV Infection by Sexual Transmission Increasing and Greatest Among HIV-Infected Men
Low SVR Rates With Peginterferon/Ribavirin After Liver Transplantation in HIV/HCV-Coinfected Patients
Risk of TB-Associated Immune Reconstitution Inflammatory Syndrome Increases With Earlier ART and Lower CD4+ Cell Count
Predictive Value of Current Noninvasive Models for Assessing Fibrosis in HIV/HCV-Coinfected Patients May Be Improved With New Statistical Methods
CPG 7909 Adjuvant Improves Immunogenic Response to Hepatitis B Vaccine in HIV-Infected Individuals
Transient Elastometry Has Poor Ability to Distinguish Between Mild and Moderate Liver Fibrosis in HIV/HCV-coinfected Patients

Expert Analysis

Hepatitis and Opportunistic Diseases

Faculty:
Richard E. Chaisson, MD Bruce Polsky, MD Jürgen K. Rockstroh, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recall recent data regarding the incidence of opportunistic infections and their relative impact on mortality and morbidity
Summarize the impact of hepatitis C virus coinfection in HIV-infected patients on treatment outcomes
Explain updates on hepatitis B virus vaccination and treatment in the setting of HIV coinfection

CME CREDIT INFORMATION

Release Date: 05/09/07

Expiration Date: 05/08/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.4 contact hours (0.14 CEUs)

Registered Nurses: 1.6 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.